Tag: NEXLIZET

Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

Coronary/Structural Heart by 0 comments

– Submitted four efficacy supplements seeking inclusion of CV risk reduction and expansion of LDL-C lowering –  – Anticipated approvals in U.S. in the first half of 2024 –  ANN ARBOR, Mich., June 01, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced […]

Continue Reading →

Esperion Supports Collaborative Study with an Integrated and Learning Health Care Delivery System in Northern California to Study the Effects of NEXLIZET® (bempedoic acid and ezetimibe) in Reducing LDL-Cholesterol Following a Recent Acute Coronary Syndrome Event

Coronary/Structural Heart by 0 comments

– The CLEAR ACS trial is designed to evaluate the efficacy of NEXLIZET on short-term LDL-C lowering following those with a recent ACS event and at very high risk of recurrent CV event in a diverse patient population that is […]

Continue Reading →